Zacks: Can-Fite Biopharma Ltd (CANF) Given $29.99 Consensus Target Price by Brokerages
Shares of Can-Fite Biopharma Ltd (NASDAQ:CANF) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating. Can-Fite Biopharma’s rating score has improved by 50% in the last three months as a result of various analysts’ ratings changes.
Brokerages have set a 12 month consensus price target of $29.99 for the company and are forecasting that the company will post ($1.94) EPS for the current quarter, according to Zacks. Zacks has also assigned Can-Fite Biopharma an industry rank of 69 out of 256 based on the ratings given to its competitors.
Separately, HC Wainwright reissued a “buy” rating on shares of Can-Fite Biopharma in a research report on Tuesday, March 26th.
Can-Fite Biopharma (NASDAQ:CANF) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.18) EPS for the quarter. The company had revenue of $0.29 million for the quarter.
About Can-Fite Biopharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.